This article has been corrected from a previous version to note that Thermo Fisher Scientific doesn't market LDTs, it only sells lab tools to the lab industry.
MOUNTAIN VIEW, California (GenomeWeb) – The Centers for Medicare & Medicaid Services' broad draft national coverage policy for next-generation sequencing cancer panels has some industry players wondering whether commercial payors will take a similar position.
Get the full story with
360Dx Premium
Only $95 for the
first 90 days*
360Dx Premium gives you:
✔ Full site access
✔ Interest-based email alerts
✔ Access to archives
Never miss another important industry story.
Try 360Dx Premium now.
You may already have institutional access!
Check if I qualify.
Already a 360Dx or GenomeWeb Premium member?
Login Now.
*Before your trial expires, we’ll put together a custom quote with your long-term premium options.
